Terahertz Optomagnetism:Nonlinear THz Excitation of GHz Spin Waves in Antiferromagnetic FeBO3

A nearly single cycle intense terahertz (THz) pulse with peak electric and magnetic fields of 0.5 MV/cm and 0.16 T, respectively, excites both modes of spin resonances in the weak antiferromagnet FeBO3. The high frequency quasiantiferromagnetic mode is excited resonantly and its amplitude scales linearly with the strength of the THz magnetic field, whereas the low frequency quasiferromagnetic mode is excited via a nonlinear mechanism that scales quadratically with the strength of the THz electric field and can be regarded as a THz inverse Cotton-Mouton effect. THz optomagnetism is shown to be more energy efficient than similar effects reported previously for the near-infrared spectral range

EFFECT OF THE GAS MEDIA AND TEMPERATURE REGIMES OF ANNEALING ON THE PHASE COMPOSITION OF IRON BORATE FeBO3

Iron borate FeBO3 crystals are annealed in neutral, oxidizing, and reducing gas media on a specially designed setup. The effect of the chemical medium and annealing modes on the surface morphology and phase composition of the samples is established.Исследования выполнены при финансовой поддержке РФФИ, проект № 19-29-12016-мк, в части разработки экспериментальной установки и получения кристаллических образцов. Рентгеновские и электронно-микроскопические измерения проведены при под-держке Министерства науки и высшего образования РФ в рамках выполнения работ по Государственному заданию ФНИЦ «Кристаллография и фотоника» с использованием оборудования ЦКП (проект RFMEFI62119X0035)

HYPERFINE INTERACTIONS IN IRON BORATE FeBO3

For the FeBO3 single crystal, the values of isomer shift, quadrupole constant and magnetic hyperfine field were determined for over a wide temperature range.Исследования выполнены при финансовой поддержке РФФИ, проект № 19-29-12016-мк, в части мёссбауэровских исследований и теоретического анализа. Рентгеновские измерения проведены при поддержке Министерства науки и высшего образования РФ в рамках выполнения работ по Государственному заданию ФНИЦ «Кристаллография и фотоника» с использованием оборудования ЦКП (проект RFMEFI62119X0035)

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Modelling the magnetic dipole

Three different models of a magnetic dipole, viz., a uniformly magnetised sphere, a circular current loop and a pair of fictitious magnetic charges, have been systematically analysed within the formalism based on the vector potential of the magnetic field. The expressions of the potentials and magnetic fields produced by each dipole model have been obtained. A computer code has been put forward in order to visualise magnetic field lines for different dipole models. It has been shown that the magnetic field outside the uniformly magnetised sphere coincides with that of a point dipole. The other two models give considerably different results at distances small or intermediate in comparison with the dipole size